Biotech Values

[DFRAI]

Anavex citations - comments much appreciated

I find the totality of Anavex articles very supportive and profound as it seems that it has a solution to neuro diseases such as AD. At this time, it seems to be much better than all approved AD drugs on the market.

“In addition to the measured cognitive and functional benefits witnessed so far, an overall improvement in mood and decrease in agitation has been anecdotally reported,” Associate Professor MacFarlane said.
At the time of these announcements, Australian media focused on two of the participants who regained ‘lost’ skills. One of whom was able to play the piano again and another who rediscovered her art skills. While this is great news Associate Professor MacFarlane did urge some caution stating “we believe that extending the study will lead us to an increased understanding of the long-term effects of Anavex 2-73.”

https://www.dementiadaily.org.au/the-facts-the-australian-anavex-2-73-alzheimers-clinical-trial/

The primary end points were safety, tolerability, and pharmacokinetics. The exploratory measures included the P300 electroencephalogram, MMSE score, the Computerized Cogstate Alzheimer’s Battery, and the ADCS-ADL. The Hamilton Depression (HAM-D) Scale was also employed as a neuropsychiatric symptom measure.

The cohort had low baseline depression scores, with a mean score of 2 on the HAM-D. By the study’s end, it had decreased to a mean of 1 point. Patients also reported improvements in their ability to work or do other activities, and in anxiety, agitation, hypochondriasis, and insight.

Electrophysiologic Measures

The P300 wave amplitude showed a small initial increase from about 6 microvolts to 7 microvolts by four weeks, and then returned to about 6 microvolts until about week 32. Thereafter, it steadily improved to about 8 microvolts by 57 weeks—a level usually seen in healthy age-matched controls. There was a significant separation from the P300 decline seen in a matched historical Alzheimer’s disease cohort, which decreased to about 4 microvolts over a 52-week period while patients were taking donepezil.

Researchers used a second historical control group to assess changes on the Computerized Cogstate Alzheimer’s Battery. All subjects in a large Australian prospective cohort study, called AIBL (Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing), were taking standard of care Alzheimer’s drugs. Compared with that cohort, the ANAVEX 2-73 group experienced benefits in processing speed, attention, and working memory, which became statistically significant at week 31 and continued to improve.

At 57 weeks, patients’ mean MMSE score was near the baseline mean score of 20.
http://www.mdedge.com/neurologyreviews/article/130412/alzheimers-cognition/can-sigma-1-agonist-stabilize-cognition-and

In a scientific study conducted in France at the University of Montpellier and INSERM, ANAVEX 2-73 demonstrated disease-modifying effects, including the ability to repair normal mitochondrial functionality in the hippocampus, the part of the brain involved with learning, memory and emotions.

http://mitochondrialdiseases.org/anavex-2-73-linking-mitochondrial-functionality-to-alzheimers/
http://www.anavex.com/files/1303_ADPD_Valentine.pdf